Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder
Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the […]
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying […]
Oblato Announces the First Enrollment in a Phase 1 Clinical Trial for an Oral Formulation of OKN-007 in Recurrent High-Grade Glioma Patients
Oblato, a subsidiary company of HLB Therapeutics in Korea, has announced the first enrollment for […]
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors
IDEAYA Biosciences, a precision medicine oncology company committed to the discovery and development of targeted […]
Landmark Study Finds Pison AI Technology Can Detect Neurological Disorder in ALS Patients
Pison, the pioneers behind AI-powered neural biosensors for health, wellness, and 3D touchless smart device […]
Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects
Lynk Pharmaceuticals, an innovative clinical-stage company, announced that it has recently completed phase I trials […]
Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent’s Ongoing Orion Clinical Study
Vivani Medical, an emerging biopharmaceutical company that develops miniaturized, subdermal implants has announced that the […]
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment
CANbridge Pharmaceuticals, a global biopharmaceutical company, with a foundation in China, committed to the research, […]
ReCode Therapeutics Announces First Participants Dosed in a Healthy Volunteer Clinical Trial for the Treatment of Primary Ciliary Dyskinesia
ReCode Therapeutics, a private, clinical-stage genetic medicines company using superior delivery to power the next […]
AusperBio Announces First-in-Human Dosing of AHB-137, an Antisense Oligonucleotide Drug Candidate for the Treatment of Chronic Hepatitis B
AusperBio has announced the completion of the first cohort dosing in a Phase 1 clinical […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more